Loading clinical trials...
Loading clinical trials...
A Phase III Multi-Center, OpenLabel, Follow-Up Study to Assess the Safety & Efficacy of Epratuzumab in Patients With Acute Severe SLE Flares Excluding the Renal or Neurologic Systems
Epratuzumab is an investigational antibody designed to help treat SLE. The purpose is to evaluate safety and long term efficacy in concert with standard SLE treatments
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Birmingham, Alabama, United States
Tucson, Arizona, United States
Los Angeles, California, United States
Upland, California, United States
Farmington, Connecticut, United States
Washington D.C., District of Columbia, United States
Aventura, Florida, United States
Chicago, Illinois, United States
Baltimore, Maryland, United States
New York, New York, United States
Start Date
January 1, 2007
Last Updated
May 21, 2014
Epratuzumab
DRUG
Lead Sponsor
UCB Pharma
NCT06647069
NCT07371468
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06333483